We collaborate with leading biopharma companies to explore a wide range of disease areas. These collaborations leverage our partners' deep domain expertise in the therapeutic area and BigHat’s unique capabilities in de novo design and multiparameter optimization of complex antibodies which rapidly advance potential therapies to the clinic together. A truly end-to-end design and development of the next-generation antibody formats for safer and more effective medicines.
We partner with leading biopharma companies to apply the Milliner platform to existing antibodies and fragments with known therapeutic properties. In these partnership programs, Milliner’s multiparameter optimization capabilities bring the partner’s initial sequences to a truly clinic-ready stage with optimized affinity and desired biophysical properties and thereby offer the potential opportunity for best-in-class products with enhanced clinical safety, efficacy, and tolerability.
Differentiated end-to-end discovery and development platform that pairs machine learning with a high-speed scaled wet lab
Deep experienced developing antibody therapies from target ID to animal studies and beyond
Nimble and efficient processes, from onboarding to collaborative updates to selecting final sequences
Collaborative team responsive to partner’s key needs and goals
Work hand-in-hand with leading researchers and practitioners applying AI/ML to drug discovery and development
A track record of successful collaborations and satisfied partners
“Completion of the first stage of Amgen’s research collaboration with BigHat demonstrated the ability of their platform to quickly and significantly optimize next-generation single-domain antibodies, validating the platform as a path to generating target binders with improved properties compared with the original repertoire identified by traditional technologies.”
“This agreement with BigHat expands Merck’s strategy of applying AI/ML across our drug discovery capabilities. We look forward to working with the team to leverage BigHat’s technology and expertise in enabling molecular design of novel biologic candidates.”
